Skip to content

Adoptive immunotherapy using donor liver graft derived natural killer (NK) cells for preventing severe infection after liver transplantation

Adoptive immunotherapy using donor liver graft derived natural killer (NK) cells for preventing severe infection after liver transplantation - Liver NK cell therapy for preventing infection after liver transplant

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000019183
Enrollment
37
Registered
2015-11-01
Start date
2015-11-25
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

decompensated liver cirrhosis patients who will receive liver transplantation

Interventions

Sponsors

Hiroshima University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Recipient 1) decompensated liver cirrhotic patients who will receive liver transplantation 2) 20 years old or older 3) written informed consent from patients or legal guardian Donor 1) healthy person who will receive living donor liver operation 2) 20 years old or older 3) written informed consent

Exclusion criteria

Exclusion criteria: 1) patients who will receive re-transplantation 2) patients who will receive deceased donor liver transplantation

Design outcomes

Primary

MeasureTime frame
Incidence of blood stream infection during one month after liver transplantation

Secondary

MeasureTime frame
1. Overall survival (6 months, 1 and 3 years) 2. Effect on immunological reaponse after liver transplantation 3. Incidence of recurrence of hepatocellular carcinoma and de novo malignancy 4. Incidence of other infectious disease 5. Safety evaluation

Countries

Japan

Contacts

Public ContactMasahiro Ohira

Hiroshima University Hospital Medical Center for Translational and Clinical Research

mohira@hiroshima-u.ac.jp082-257-5222

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026